{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:17:14Z","timestamp":1785338234248,"version":"3.55.0"},"reference-count":75,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Malignant ovarian germ cell tumors are rare malignancies primarily affecting adolescents and young adults. Management must balance curative intent with fertility preservation. This review highlights recent advances in malignant ovarian germ cell tumor management, focusing on risk-stratified approaches, surgical techniques, somatic transformation, and long-term surveillance. The bleomycin\/etoposide\/cisplatin regimen remains the first-line therapy. Fertility-sparing surgery, including unilateral salpingo-oophorectomy with minimal staging, is recommended for adolescent and young adult patients. Chemotherapy is not recommended for those with surgically resected immature teratomas. In advanced-stage malignant ovarian germ cell tumors, adjuvant chemotherapy may be considered for frail patients with chemosensitive tumors. Given the risk of late complications, long-term surveillance and lifelong care are essential for survivors. Future directions emphasize molecular profiling to guide personalized treatment. Multidisciplinary care, precision surgery, and tailored systemic therapies continue to improve survival while preserving quality of life. Collaborative trials are crucial for standardizing salvage approaches and mitigating long-term toxicities, ensuring optimal outcomes for this young, survivorship-focused population.<\/jats:p>","DOI":"10.1097\/og9.0000000000000095","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:11:45Z","timestamp":1753999905000},"page":"e095","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Updates in the Management of Malignant Ovarian Germ Cell Tumors"],"prefix":"10.1097","volume":"2","author":[{"given":"Jie","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8]]},"reference":[{"key":"R1-20250731","doi-asserted-by":"crossref","first-page":"e2027738","DOI":"10.1001\/jamanetworkopen.2020.27738","article-title":"Trends in cancer incidence in US adolescents and young adults, 1973-2015","volume":"3","author":"Scott","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R2-20250731","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ygyno.2020.05.007","article-title":"Contemporary management of ovarian germ cell tumors and remaining controversies","volume":"158","author":"Veneris","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R5-20250731","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R6-20250731","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.annonc.2022.01.002","article-title":"Testicular seminoma and non-seminoma: ESMO-EURACAN clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oldenburg","year":"2022","journal-title":"Ann Oncol"},{"issue":"suppl 4","key":"R7-20250731","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdy001","article-title":"Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Ray-Coquard","year":"2018","journal-title":"Ann Oncol"},{"key":"R8-20250731","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/j.ejca.2014.03.288","article-title":"Prognostic factors in malignant ovarian germ cell tumours (the Surveillance, Epidemiology and End Results experience 1978-2010)","volume":"50","author":"Solheim","year":"2014","journal-title":"Eur J Cancer"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejca.2019.06.005","article-title":"Overview of non-epithelial ovarian tumours: incidence and survival in the Netherlands, 1989-2015","volume":"118","author":"van der Hel","year":"2019","journal-title":"Eur J Cancer"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ygyno.2013.08.028","article-title":"Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009)","volume":"131","author":"Solheim","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R11-20250731","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canep.2009.04.015","article-title":"A mini-review of familial ovarian germ cell tumors: an additional manifestation of the familial testicular germ cell tumor syndrome","volume":"33","author":"Giambartolomei","year":"2009","journal-title":"Cancer Epidemiol"},{"key":"R12-20250731","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1210\/er.2012-1045","article-title":"Molecular characteristics of malignant ovarian germ cell tumors and comparison with testicular counterparts: implications for pathogenesis","volume":"34","author":"Kraggerud","year":"2013","journal-title":"Endocr Rev"},{"key":"R13-20250731","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/joim.13778","article-title":"Malignant ovarian and testicular germ cell tumors: common characteristics but different prognoses","volume":"295","author":"Sk\u00f6ld","year":"2024","journal-title":"J Intern Med"},{"key":"R14-20250731","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/nrc1568","article-title":"Testicular germ-cell tumours in a broader perspective","volume":"5","author":"Oosterhuis","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"R15-20250731","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.eururo.2014.12.040","article-title":"Exome-wide sequencing shows low mutation rates and identifies novel mutated genes in seminomas","volume":"68","author":"Cutcutache","year":"2015","journal-title":"Eur Urol"},{"key":"R16-20250731","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2018.08.013","article-title":"The genetic landscape of 87 ovarian germ cell tumors","volume":"151","author":"Van Nieuwenhuysen","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R17-20250731","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1038\/s41467-021-23681-0","article-title":"Analysis of the genomic landscape of yolk sac tumors reveals mechanisms of evolution and chemoresistance","volume":"12","author":"Zong","year":"2021","journal-title":"Nat Commun"},{"key":"R18-20250731","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/MOU.0000000000000347","article-title":"Testicular germ cell tumor genomics","volume":"27","author":"Woldu","year":"2017","journal-title":"Curr Opin Urol"},{"key":"R19-20250731","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1002\/cncr.25794","article-title":"KIT gene mutation and amplification in dysgerminoma of the ovary","volume":"117","author":"Cheng","year":"2011","journal-title":"Cancer"},{"key":"R20-20250731","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1097\/PAS.0000000000001354","article-title":"Fluorescent in situ hybridization analysis for 12p alterations in sarcomatoid yolk sac tumors","volume":"43","author":"Idrees","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"R21-20250731","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/JCO.2014.58.3369","article-title":"Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States","volume":"33","author":"Frazier","year":"2015","journal-title":"J Clin Oncol"},{"key":"R22-20250731","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejca.2019.03.001","article-title":"A multicentre retrospective cohort study of ovarian germ cell tumours: evidence for chemotherapy de-escalation and alignment of paediatric and adult practice","volume":"113","author":"Newton","year":"2019","journal-title":"Eur J Cancer"},{"key":"R23-20250731","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ygyno.2015.06.029","article-title":"Development of a risk stratification system to guide treatment for female germ cell tumors","volume":"138","author":"Meisel","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R24-20250731","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ygyno.2022.12.022","article-title":"Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management","volume":"170","author":"Liu","year":"2023","journal-title":"Gynecol Oncol"},{"key":"R25-20250731","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1136\/ijgc-2024-005489","article-title":"Predicting outcomes in malignant ovarian germ cell tumors using the modified International Germ Cell Cancer Collaborative Group classification system","volume":"34","author":"Zhang","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"R26-20250731","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/annonc\/mdw563","article-title":"The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study","volume":"28","author":"Mangili","year":"2017","journal-title":"Ann Oncol"},{"key":"R27-20250731","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/bjc.2011.267","article-title":"Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary","volume":"105","author":"Mahdi","year":"2011","journal-title":"Br J Cancer"},{"key":"R28-20250731","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jpedsurg.2003.11.027","article-title":"Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study","volume":"39","author":"Billmire","year":"2004","journal-title":"J Pediatr Surg"},{"key":"R29-20250731","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ygyno.2008.04.022","article-title":"The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary","volume":"110","author":"Kumar","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R30-20250731","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejogrb.2022.02.013","article-title":"Surgical management and outcomes for stage 1 malignant ovarian germ cell tumours: a UK multicentre retrospective cohort study","volume":"271","author":"Graham","year":"2022","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R31-20250731","doi-asserted-by":"crossref","first-page":"102453","DOI":"10.1016\/j.eclinm.2024.102453","article-title":"Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective","volume":"69","author":"Pashankar","year":"2024","journal-title":"eClinicalMedicine"},{"key":"R32-20250731","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3390\/diagnostics13091516","article-title":"Immature teratoma: diagnosis and management\u2013a review of the literature","volume":"13","author":"Moraru","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"R33-20250731","doi-asserted-by":"crossref","first-page":"100976","DOI":"10.1016\/j.gore.2022.100976","article-title":"Early stage ovarian immature teratoma, surveillance or chemotherapy after surgery? A propensity score matched analysis","volume":"40","author":"Zhang","year":"2022","journal-title":"Gynecol Oncol Rep"},{"key":"R34-20250731","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/0003-4819-87-3-293","article-title":"Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer","volume":"87","author":"Einhorn","year":"1977","journal-title":"Ann Intern Med"},{"key":"R35-20250731","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJM198706043162302","article-title":"Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide","volume":"316","author":"Williams","year":"1987","journal-title":"N Engl J Med"},{"key":"R36-20250731","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ygyno.2018.05.025","article-title":"Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?","volume":"150","author":"Shah","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R37-20250731","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2018.03.004","article-title":"Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: a report of the Malignant Germ Cell International Consortium","volume":"98","author":"Frazier","year":"2018","journal-title":"Eur J Cancer"},{"key":"R38-20250731","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.3802\/jgo.2025.36.e49","article-title":"Comparison of carboplatin-based chemotherapy versus cisplatin-based chemotherapy in the treatment of malignant gonadal germ cell tumor: a systematic review and meta-analysis","volume":"36","author":"Zhang","year":"2025","journal-title":"J Gynecol Oncol"},{"key":"R39-20250731","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/ijgc-2023-004624","article-title":"Advanced ovarian yolk sac tumor: upfront surgery or neoadjuvant chemotherapy followed by interval debulking?","volume":"34","author":"Zhang","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"R40-20250731","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000509189","article-title":"Clinicopathological features, prognostic factors, survival trends, and treatment of malignant ovarian germ cell tumors: a SEER database analysis","volume":"44","author":"Guo","year":"2021","journal-title":"Oncol Res Treat"},{"key":"R41-20250731","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JOP.2016.011411","article-title":"Salvage therapy for patients with germ cell tumor","volume":"12","author":"Rashdan","year":"2016","journal-title":"J Oncol Pract"},{"key":"R42-20250731","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2014.59.4325","article-title":"High-dose chemotherapy for recurrent ovarian germ cell tumors","volume":"33","author":"Reddy Ammakkanavar","year":"2015","journal-title":"J Clin Oncol"},{"key":"R43-20250731","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2011.06.019","article-title":"Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and\/or multiply relapsed germ cell tumors","volume":"60","author":"Oechsle","year":"2011","journal-title":"Eur Urol"},{"key":"R44-20250731","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/14737140.2018.1450630","article-title":"Therapeutic approaches for refractory germ cell cancer","volume":"18","author":"Oing","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"R45-20250731","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1038\/s41379-022-01136-1","article-title":"Molecular correlates of male germ cell tumors with overgrowth of components resembling somatic malignancies","volume":"35","author":"Wyvekens","year":"2022","journal-title":"Mod Pathol"},{"key":"R46-20250731","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/1097-0142(19841101)54:9<1824::AID-CNCR2820540910>3.0.CO;2-J","article-title":"The development of non-germ cell malignancies within germ cell tumors: a clinicopathologic study of 11 cases","volume":"54","author":"Ulbright","year":"1984","journal-title":"Cancer"},{"key":"R47-20250731","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1097\/PAS.0000000000000262","article-title":"\u201cSomatic-type\u201d malignancies arising from testicular germ cell tumors: a clinicopathologic study of 124 cases with emphasis on glandular tumors supporting frequent yolk sac tumor origin","volume":"38","author":"Magers","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R48-20250731","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/PAS.0000000000001789","article-title":"Somatic-type malignancies in testicular germ cell tumors: a clinicopathologic study of 63 cases","volume":"46","author":"Hwang","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"R49-20250731","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13048-018-0476-y","article-title":"Recurrent ovarian mixed germ cell tumor with unusual malignant transformation: a case report","volume":"12","author":"Lee","year":"2019","journal-title":"J Ovarian Res"},{"key":"R50-20250731","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ygyno.2019.12.042","article-title":"Diagnosis and management of growing teratoma syndrome after ovarian immature teratoma: a single center experience","volume":"157","author":"Wang","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R51-20250731","first-page":"195","article-title":"Squamous cell carcinoma arising in mature cystic teratoma of ovary","volume":"5","author":"Patni","year":"2014","journal-title":"J Midlife Health"},{"key":"R52-20250731","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.3802\/jgo.2025.36.e54","article-title":"Ovarian squamous cell carcinoma: clinicopathological features, prognosis and immunotherapy outcomes","volume":"36","author":"Zhang","year":"2025","journal-title":"J Gynecol Oncol"},{"key":"R53-20250731","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bpa.12832","article-title":"cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading","volume":"30","author":"Louis","year":"2020","journal-title":"Brain Pathol"},{"key":"R54-20250731","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1097\/PAS.0000000000001703","article-title":"\u201cEmbryonic-type neuroectodermal tumor\u201d should replace \u201cprimitive neuroectodermal tumor\u201d of the testis and gynecologic tract: a rationale for new nomenclature","volume":"45","author":"Flood","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"R55-20250731","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13023-019-1106-5","article-title":"Ovarian primary primitive neuroectodermal tumor: a review of cases at PUMCH and in the published literature","volume":"14","author":"Chao","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"R56-20250731","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2016.01.015","article-title":"New brain tumor entities emerge from molecular classification of CNS-PNETs","volume":"164","author":"Sturm","year":"2016","journal-title":"Cell"},{"key":"R58-20250731","doi-asserted-by":"crossref","first-page":"100702","DOI":"10.1016\/j.modpat.2024.100702","article-title":"Molecular diversity of embryonic-type neuroectodermal tumors arising from testicular germ cell tumors","volume":"38","author":"Zong","year":"2025","journal-title":"Mod Pathol"},{"key":"R59-20250731","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1158\/1055-9965.EPI-15-1153","article-title":"Long-term relative survival after diagnosis of testicular germ cell tumor","volume":"25","author":"Kvammen","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R60-20250731","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2008.20.9189","article-title":"Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study","volume":"27","author":"Matei","year":"2009","journal-title":"J Clin Oncol"},{"key":"R61-20250731","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/ehf2.12048","article-title":"The impact of cisplatinum-based chemotherapy on ventricular function and cardiovascular risk factors in female survivors after malignant germ cell cancer","volume":"2","author":"Murbraech","year":"2015","journal-title":"ESC Heart Fail"},{"key":"R62-20250731","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ygyno.2017.02.006","article-title":"Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer","volume":"145","author":"Skalleberg","year":"2017","journal-title":"Gynecol Oncol"},{"key":"R63-20250731","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ygyno.2019.08.017","article-title":"Fertility-sparing surgery for treatment of non-epithelial ovarian cancer: oncological and reproductive outcomes in a prospective nationwide population-based cohort study","volume":"155","author":"Johansen","year":"2019","journal-title":"Gynecol Oncol"},{"key":"R64-20250731","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.7150\/jca.26674","article-title":"Fertility sparing management in non-epithelial ovarian cancer: which patients, what procedure and what outcome?","volume":"9","author":"Thomakos","year":"2018","journal-title":"J Cancer"},{"key":"R65-20250731","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.3390\/cancers15164170","article-title":"Obstetric results after fertility-sparing management of non-epithelial ovarian cancer","volume":"15","author":"Pi\u0105tek","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R66-20250731","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMra1614676","article-title":"Fertility preservation in women","volume":"377","author":"Donnez","year":"2017","journal-title":"N Engl J Med"},{"key":"R67-20250731","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ygyno.2015.09.013","article-title":"Ovarian cancer in France: trends in incidence, mortality and survival, 1980\u20132012","volume":"139","author":"Tr\u00e9tarre","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R68-20250731","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/1097-0142(19850715)56:2<243::AID-CNCR2820560206>3.0.CO;2-T","article-title":"Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary: a Gynecologic Oncology Group Study (a final report)","volume":"56","author":"Slayton","year":"1985","journal-title":"Cancer"},{"key":"R69-20250731","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1200\/JCO.1983.1.10.645","article-title":"Combination cisplatin, vinblastine, and bleomycin chemotherapy (PVB) for malignant germ-cell tumors of the ovary","volume":"1","author":"Carlson","year":"1983","journal-title":"J Clin Oncol"},{"key":"R70-20250731","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1200\/JCO.1994.12.4.701","article-title":"Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group","volume":"12","author":"Williams","year":"1994","journal-title":"J Clin Oncol"},{"key":"R71-20250731","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1006\/gyno.1998.5047","article-title":"Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study","volume":"70","author":"Dimopoulos","year":"1998","journal-title":"Gynecol Oncol"},{"key":"R72-20250731","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ygyno.2004.07.044","article-title":"Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group","volume":"95","author":"Williams","year":"2004","journal-title":"Gynecol Oncol"},{"key":"R73-20250731","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1200\/JCO.2004.01.006","article-title":"Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: a Pediatric Intergroup Study\u2014Pediatric Oncology Group 9048 and Children's Cancer Group 8891","volume":"22","author":"Rogers","year":"2004","journal-title":"J Clin Oncol"},{"key":"R74-20250731","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/bjc.1990.272","article-title":"\u201cJEB\u201d\u2014a carboplatin based regimen for malignant germ cell tumours in children","volume":"62","author":"Pinkerton","year":"1990","journal-title":"Br J Cancer"},{"key":"R75-20250731","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1200\/JCO.23.02542","article-title":"Paclitaxel, ifosfamide, and cisplatin as initial salvage chemotherapy for germ cell tumors: long-term follow-up and outcomes for favorable- and unfavorable-risk disease","volume":"42","author":"Gleeson","year":"2024","journal-title":"J Clin Oncol"},{"key":"R76-20250731","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/annonc\/mdq575","article-title":"A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer: an intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)","volume":"22","author":"Daugaard","year":"2011","journal-title":"Ann Oncol"},{"key":"R77-20250731","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.1998.16.7.2500","article-title":"Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor","volume":"16","author":"Loehrer","year":"1998","journal-title":"J Clin Oncol"}],"container-title":["O&amp;G Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/og9.0000000000000095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:11:55Z","timestamp":1753999915000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/og9.0000000000000095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":75,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/og9.0000000000000095","relation":{},"ISSN":["2994-9726"],"issn-type":[{"value":"2994-9726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"2025-04-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}